FDA approves long-acting ESA for dialysis-related anemia in children, adolescents

Publish date: June 7, 2018 By Christopher Palmer  Hematology News The Food and Drug Administration has approved methoxy polyethylene glycol-epoetin beta (Mircera) for the treatment of dialysis-related anemia in pediatric patients aged 5-17 years with chronic kidney disease whose hemoglobin had been stabilized with an erythropoiesis-stimulating agent (ESA). The approval for this long-acting...